Abstract
The application of various molecular modeling techniques has been recently reported in the design of several new cysteine protease inhibitors. Computational chemistry techniques have been used to understand and predict enzyme-inhibitor interactions and also to study enzyme mechanism and inhibitor reactivity. This review focuses on examples that use structure-based design or reflect cysteine proteases as a target class. In several cases X-ray crystallography and molecular modeling have significantly facilitated the inhibitor design process. Cysteine proteases can present extra challenges in molecular modeling, due to the covalent binding modes and the reactive nature of many of the inhibitors. We also discuss some of the key challenges in developing new tools to evaluate these properties and help in making informed decisions about new templates and leads.
Keywords: molecular modeling, computational chemistry, computer-aided drug design, computer-based design, cystein protease design
Current Pharmaceutical Design
Title: Molecular Modeling in Cysteine Protease Inhibitor Design
Volume: 8 Issue: 18
Author(s): Mika K. Lindvall
Affiliation:
Keywords: molecular modeling, computational chemistry, computer-aided drug design, computer-based design, cystein protease design
Abstract: The application of various molecular modeling techniques has been recently reported in the design of several new cysteine protease inhibitors. Computational chemistry techniques have been used to understand and predict enzyme-inhibitor interactions and also to study enzyme mechanism and inhibitor reactivity. This review focuses on examples that use structure-based design or reflect cysteine proteases as a target class. In several cases X-ray crystallography and molecular modeling have significantly facilitated the inhibitor design process. Cysteine proteases can present extra challenges in molecular modeling, due to the covalent binding modes and the reactive nature of many of the inhibitors. We also discuss some of the key challenges in developing new tools to evaluate these properties and help in making informed decisions about new templates and leads.
Export Options
About this article
Cite this article as:
Lindvall K. Mika, Molecular Modeling in Cysteine Protease Inhibitor Design, Current Pharmaceutical Design 2002; 8 (18) . https://dx.doi.org/10.2174/1381612023394142
DOI https://dx.doi.org/10.2174/1381612023394142 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements